Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-2303 COVID-19 vaccine with influenza vaccine
NCT06279871Phase 3Completed
- Sponsor
- Arcturus Therapeutics
- Start
- Mar 2024
- Primary completion
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, single-blind trial of ARCT-2303 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Arcturus Therapeutics. Primary endpoints: Geometric Mean Titers of SARS-CoV-2 Neutralizing Antibody Against Omicron XBB.1.5 at Day 29, Number of Participants With Seroconversion to SARS-CoV-2 Neutralizing Antibody Against Omicron XBB.1.5 at Day 29 and 2 more. Started Mar 2024; status: completed.
02
Drugs
ARCT-2303
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06279871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279871.